Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

• Main Authors: Filiz Cicek (Author), Sascha Troschke-Meurer (Author), Kiraz Ceylan (Author), Luciana J. Jahns (Author), Maxi Zumpe (Author), Nikolai Siebert (Author), Karoline Ehlert (Author), Holger N. Lode (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninety-nine patients with high-risk neuroblastoma recei...